ID   HB-CLS-2
AC   CVCL_6214
SY   HBCLS2
DR   CLS; 300191
DR   Wikidata; Q54881348
RX   PubMed=28196595;
RX   PubMed=29732388;
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   HLA typing: A*24:02:01,32:01:01; B*27:02:00,55:01:01; C*02:02:02,03:03:01; DPB1*02:01,03:01; DQA1*01:05:01,04:01:01; DQB1*04:02:01,05:01:01; DRB1*08:01:01,10:01:01 (CLS=300191).
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): CLS=300191
ST   Amelogenin: X,Y
ST   CSF1PO: 7,10
ST   D13S317: 11,12
ST   D16S539: 12
ST   D18S51: 15,17
ST   D21S11: 32.2,35.2
ST   D3S1358: 16
ST   D5S818: 10,12
ST   D7S820: 8,9
ST   D8S1179: 13
ST   FGA: 21,23
ST   Penta D: 11,13
ST   Penta E: 13
ST   TH01: 8,10
ST   TPOX: 11
ST   vWA: 15,18
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 17
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//